Loading…

Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' Orbitopathy

Purpose: Orbital fibroblasts are involved in pathogenesis of Graves' orbitopathy (GO). Fibroblast growth factor (FGF) affects fibroblasts of GO. This study aims to investigate the roles of FGF and FGF receptor (FGFR) in GO. Methods: Serum FGF proteins and orbital fibroblast FGFR proteins and mR...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2021-01, Vol.29 (1), p.193-202
Main Authors: Shih, Shyang-Rong, Liao, Shu-Lang, Shih, Chih-Wei, Wei, Yi-Hsuan, Lu, Ting-Xuan, Chou, Chien-Hsiang, Yen, Er-Yen, Chang, Yi-Cheng, Lin, Chia-Chi, Chi, Yu-Chiao, Yang, Wei-Shiung, Tsai, Feng-Chiao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: Orbital fibroblasts are involved in pathogenesis of Graves' orbitopathy (GO). Fibroblast growth factor (FGF) affects fibroblasts of GO. This study aims to investigate the roles of FGF and FGF receptor (FGFR) in GO. Methods: Serum FGF proteins and orbital fibroblast FGFR proteins and mRNAs were measured in GO patients and controls. Orbital fibroblasts of GO were cultured and accessed for changes in proliferation (by nuclei number and MTT), myofibroblastic differentiation (by α-SMA), and adipogenesis (by oil droplets using Oil Red O stain) under FGF1 with or without FGFR inhibitors (FGFRi). Results: Serum FGF1 and FGF2 were increased in GO patients. FGFR1 was the most abundantly expressed FGFR in GO orbital fibroblasts. FGF1 increased GO fibroblast proliferation/adipogenesis and suppressed myofibroblastic differentiation, while FGFRi reversed these effects. Conclusion: FGF signaling may be involved in GO pathogenesis. Manipulation of FGF-FGFR pathway for GO treatment is worthy of further investigation. Registration number on Clinicaltrials.gov: NCT03324022.
ISSN:0927-3948
1744-5078
DOI:10.1080/09273948.2019.1672196